Chantix, Zyban Need Safety Studies In Patients With Mental Illness
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's mandate, part of a response to neuropsychiatric adverse events that also includes boxed warnings for the smoking-cessation drugs, follows a trend of requesting sicker patients in trials.